35 research outputs found
Liraglutide and semaglutide: pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetes
Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia:Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers
INTRODUCTION: People with type 2 diabetes have increased risk of dementia. Glucagonâlike peptideâ1 (GLPâ1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes. METHODS: We assessed exposure to GLPâ1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with longâterm followâup: pooled data from three randomized doubleâblind placeboâcontrolled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registryâbased cohort (120,054 patients). RESULTS: Dementia rate was lower both in patients randomized to GLPâ1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25â0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86â0.93 with yearly increased exposure to GLPâ1 RAs). DISCUSSION: Treatment with GLPâ1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes